Merck CEO Says Company on Track to Fulfill Commitment of Delivering 3.1 Million Courses of COVID Treatment Pill to U.S.
CEO Rob Davis said Merck is on track to fulfill its commitment to the U.S. of 3.1 million molnupiravir courses in the coming days.
Merck delivered 1.4 million courses to the U.S. after the Food and Drug Administration in December authorized the pill in December.
Merck beat on the top and bottom line in its earnings report.